Sacubitril (; INN) is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.
via Wikipedia infobox
{{Infobox drug | drug_name = | IUPAC_name = 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid | image = Sacubitril skeletal.svg | image_class = skin-invert-image | alt = | caption =
| tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).